Methoxy Polyethylene Glycol-Epoetin Beta (Mircera)

Mircera is covered only for treatment of anemia of chronic kidney disease in adults (on dialysis or non‑dialysis) and in pediatric patients 5–17 years on hemodialysis who are converting from another ESA, limited to FDA‑approved indications. Coverage requires documentation of CKD anemia and dialysis status, age ≥18 for non‑dialysis adults, adequate iron stores or current iron therapy, hemoglobin <10.0 g/dL for initial authorization (or <11.5 g/dL for current ESA users), prior ESA dosing for conversions (pediatric IV only), and approvals are granted for up to 12 months.

"Mircera is indicated for the treatment of anemia associated with chronic kidney disease in adult patients on dialysis"

Sign up to see full coverage criteria, indications, and limitations.